Patent · US Active

Substances and methods for the use in prevention and/or treatment in huntingon's disease

US12065509B2 · kind B2 · utility

0Cited by

0References

3Claims

0Family size

Assignee

HD IMMUNE GMBH · AT

Inventors

Oskar SMRZKA · Wien, AT
Stefan Bartl · Wien, AT
Michela Parth · Wien, AT

Key dates

Filing date	Nov 5, 2021
Grant date	Aug 20, 2024
Priority date	—
Expiry date	Nov 5, 2041

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/2835
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

A monoclonal antibody may have a binding domain that binds to a peptide of the HTT protein having the sequence of p7543 (SEQ ID No. 3). Such a monoclonal according may include a heavy chain variable region CDR1 comprising GYTFTEYT (SEQ ID No. 66), a heavy chain variable region CDR2 comprising INPNNGGT (SEQ ID No. 67), a heavy chain variable region CDR3 comprising ASLDGRDY (SEQ ID No. 68), a light chain variable region CDR1 comprising QSLLNSRTRKNY (SEQ ID No. 69), a light chain variable region CDR2 comprising WAS (SEQ ID No. 70), and/or a light chain variable region comprising KQSYNLLT (SEQ ID No. 71).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.